Development of infants at risk of hypoglycaemia – study

Collaborative study looks at development of infants at risk of hypoglycaemia

Researchers from the University of Canterburys Bioengineering Mechatronics Programme are part of a large, collaborative project looking at the development of young children who were at risk of hypoglycaemia, or low blood sugar, in their early neonatal period.

Director of the UC Mechatronics Programme, Professor Geoff Chase, says UC researchers are involved in the project because of their expertise with hyperglycaemia through the management of patients with high blood sugar at both the adult ICU at Christchurch Hospital and in extremely pre-term infants at Christchurch Womens NICU, as well as expertise in managing complex data and signals.

We model the major human physiological systems the metabolic system, the cardio-vascular system and pulmonary mechanics. We then use these models, with data in clinic, to provide better monitoring of something that cannot be measured directly with ease, or in diagnostics, or to guide treatment, he says.

The multi-disciplinary study, called CHYLD (Children with Hypoglycaemia and their Later Development), is based at The University of Auckland, led by Distinguished Professor Jane Harding from the Liggins Institute.

It was Professor Chases team that, several years ago, developed the Specialised Relative Insulin Nutrition Table (SPRINT), a laminated wheel-based system to control blood glucose levels and nutritional intakes in intensive care patients. Already proven to have saved 50 lives a year and $1m/year in costs at Christchurch Hospital, the system has now been improved and computerised.

We are very familiar with the continuous glucose monitors (CGMs) that are used in this study, says Professor Chase. These are tiny sensors which, when inserted under the skin, can sense subcutaneous glucose. To remove the need for invasive testing which was previously done by pinstick, CGMs were used to measure blood sugar concentrations of the newborn babies in the study at Waikato Hospital.

CGMs do need frequent calibration however, and can produce significant random noise. The way you calibrate the devices can change the data produced, and thus the results, so how this is done and the way that subsequent data is managed is something that best leverages engineering skills.

Hypoglycaemia in neonatal infants can cause brain damage, but currently it is not known which babies will be affected or what levels of blood sugar might trigger the damage.

The CHYLD study investigates the development of children from two neonatal studies. The first, BABIES, observed 100 newborns from the NICU at Waikato Hospital between December 2006 and February 2009. The second, Sugar Babies, recruited 514 babies between November 2008 and November 2010.

Read the rest here:
Development of infants at risk of hypoglycaemia - study

Brain & Behavior Research Foundation Scientific Council Member Karl Deisseroth, M.D., Ph.D., Elected to National …

GREAT NECK, N.Y.--(BUSINESS WIRE)--

Karl Deisseroth, M.D., Ph.D., Brain & Behavior Research Foundation Scientific Council Member, is among the 84 new members elected to the National Academy of Sciences (NAS), a prestigious non-profit organization of scientists and engineers dedicated to advancing science and promoting its uses for the greater good.

The Academy acts as an official advisor to the federal government on issues related to science and technology. Election to NAS membership is one of the highest honors that can be accorded to a scientist and recognizes those who have made distinguished and continuing achievements in original research.

Dr. Deisseroth, associate professor of bioengineering and psychiatry at Stanford University, invented optogenetics with the help of a NARSAD Young Investigator Grant. Optogenetics involves the use of light to rapidly open and close the membrane channels that make neurons fire and cease firing and allows for observation of the resulting behavior in animals. Thomas R. Insel, M.D., director of the National Institute of Mental Health says about this new technology, understanding the circuitry underlying mental disorders is a daunting task but one that becomes more attainable with each new discovery about the complex circuits involved in behavior.Optogenetics has revolutionized systems neuroscience by providing precise control over circuitry in awake, behaving animals.

Herbert Pardes, M.D., founding and current president of the Brain & Behavior Research Foundation Scientific Council, a volunteer group of 132 of the worlds leading mental health researchers (including two Nobel Prize winners), delighted at the news, saying: We are extremely proud of this recognition of Karl Deisseroths brilliant contributions and commitment to the field of brain and behavior research. Our Scientific Council is made up of the most extraordinary talent in the field, uniquely positioning it to steer continued advancements through its selection of NARSAD Grantees each year.

Dr. Deisseroth is the 12th Scientific Council Member to be elected to the National Academy of Sciences. He joins:

Huda Akil, Ph.D. Scientific Council Member Since 2002

Susan G. Amara, Ph.D. Scientific Council Member Since 2010

Fred H. Gage, Ph.D. Scientific Council Member Since 2009

Paul Greengard, Ph.D. Scientific Council Member Since 1992

View original post here:
Brain & Behavior Research Foundation Scientific Council Member Karl Deisseroth, M.D., Ph.D., Elected to National ...

American Oriental Bioengineering Announces Change of Independent Auditors

NEWARK, N.J., June 15, 2012 /PRNewswire-Asia-FirstCall/ --American Oriental Bioengineering, Inc. (the "Company", or "we"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced that the Company's audit committee has released Ernst & Young Hua Ming ("EY") as the Company's independent auditor, and at the same time has retained Weinberg & Company as its independent auditor.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

American Oriental Bioengineering, Inc. Kewa Luo (646) 367-1765

Go here to see the original:
American Oriental Bioengineering Announces Change of Independent Auditors

Lessons from epigenome evolution: Exploring the epigenome's regulatory function

Sheng Zhong, of the Institute for Genomic Biology and Department of Bioengineering at the University of Illinois. Zhong and his lab study causal relationships between gene regulation and cellular behaviors, by developing computational and experimental methods on network modeling, stem cell engineering, epigenomic and single-cell analyses. Recently he has contributed to introducing "comparative epigenomics" -- using cross-species epigenomic comparison to annotate the genomes. Credit: Photo by Kathryn Coulter, courtesy of Institute for Genomic Biology

The sequencing of the human genome has provided a wealth of genetic information, yet the goal of understanding the function of every gene remains outstanding. New research from the University of Illinois published in Cell suggests determining the purpose of genes through a new method they call "comparative epigenomics."

"Comparative epigenomics is to use interspecies comparison of DNA and histone modificationsas an approach for annotation of the regulatory genome," says Sheng Zhong, of the Institute for Genomic Biology and Department of Bioengineering at the University of Illinois.

While the genome of an organism contains all its genes, it is the epigenome that decides which are expressed, or "turned on." Though genomic science has long focused on comparative genomicscomparing the genomes of similar species and finding the commonalities to determine how common traits are regulatedcomparative epigenetics provides a more in-depth look at regulatory functions.

The researchers, led by Zhong, in collaboration with Ting Wang at Washington University, Harris Lewin, and Franklin West at University of Georgia, focused their work on three species: humans, mice, and pigs. By analyzing 9 epigenomic marks in pluripotent stem cells, they were able to create an epigenomic map for each which they could then compare.

The team concluded that, with proper analysis procedures, traces of interspecies epigenomic conservation could be identified. They then demonstrated that the conserved epigenetic markers can be effectively used to annotate the genome, clarifying the genome's regulatory function.

Understanding the genome is one of the most pressing problems for science, and this study sheds light on a promising alternative method. "Comparative epigenomics enables us to find more clues from evolution about the functions of our genomes," adds Zhong.

More information: "Comparative Epigenomic Annotation of Regulatory DNA," Shu Xiao, Dan Xie, Xiaoyi Cao, Pengfei Yu, Xiaoyun Xing, Chieh-Chun Chen, Meagan Musselman, Mingchao Xie, Franklin D. West, Harris A. Lewin, Ting Wang, Sheng Zhong. Cell doi:10.1016/j.cell.2012.04.029 (volume 149 issue 6 pp.1381 - 1392)

Journal reference: Cell

Provided by University of Illinois at Urbana-Champaign

See the article here:
Lessons from epigenome evolution: Exploring the epigenome's regulatory function

UTA’s College of Engineering introduces Bachelor of Science in Bioengineering

Starting this fall, the College of Engineering will offer a new Bachelor of Science in Bioengineering degree.

The degree will be available for entering freshmen and transfer students with fewer than 24 credits.

Bioengineering department chairman Khosrow Behbehani said the degree was created because of the increase in demand and opportunities in the field.

For almost 38 years we had the graduate program at UTA, and throughout this time we have received a lot of interest and inquiry about having a bachelors degree, Behbehani said. Given the history we have in bioengineering for almost 40 years now, we are in a good position to do so.

Engineering associate dean Lynn Peterson said the number of applications is three times than expected, and the number is expected to double by the fall.

We were expecting to have about 50 students, but we received 160 applications so far, she said. Between now and the fall, the number of applications usually doubles, and at the end of the first year, 70 percent of the students stay back. We have to plan about that now.

Two degree plans are available one with emphasis on medical imaging and another on biomaterials and tissue, said Danielle Tucker, bioengineering department academic adviser. Medical imaging is a 119 credit-hour plan, and biomaterials and tissue is a 120 credit-hour plan.

Introduction to Engineering and Introduction to Bioengineering are the two bioengineering courses that will be available for freshmen in the fall. The college is still looking for faculty to teach the Introduction to Bioengineering class. Bonnie Boardman, industrial and manufacturing systems engineering senior lecturer, will be the faculty representative for the Introduction to Engineering class.

Faculty for other courses will be hired as students progress through the degree plan. Most of the 2000 and 3000 level undergraduate classes will be joined with graduate classes and be taught by the present graduate faculty, Peterson said.

Peterson said this new degree program is expected to attract more women to the field.

See more here:
UTA’s College of Engineering introduces Bachelor of Science in Bioengineering

Stanford professor wins $500K MIT invention prize

BOSTON (AP) A Stanford University professor has won a $500,000 award from a Massachusetts Institute of Technology program in recognition of his inventions.

In awarding the 2012 Lemelson-MIT Prize, university officials on Monday called Stephen Quake "a prolific inventor with a fearless ability to explore and work across disciplines."

Quake invented a chip, similar to those in electronic devices, that lets scientists take nearly 10,000 different measurements at once. Through his work, called microfluidic large-scale integration, companies and research organizations are able to use the rubber chip technology in developing cancer drugs.

MIT officials said on the school's website that Quake's research has led to the creation of four companies and 82 patents.

The 43-year-old professor of bioengineering and applied physics also created a noninvasive prenatal testing method for detecting Down syndrome.

Stanford University officials said in a prepared statement that Quake is using a similar approach to provide tests that can show earlier and more easily whether an organ transplant recipient is rejecting an organ donation.

Quake said Monday he was "incredibly excited and humbled" by the prize.

"Hopefully, it will give me a little more credibility with the investment community as we try to commercialize our inventions," the professor told The Associated Press.

Inventor Jerome H. Lemelson and his wife founded the Lemelson-MIT Program at the university in 1994. MIT said the award Quake won is known as the "Oscar for inventors" and recognizes people who translate ideas into innovations that improve the world.

Go here to read the rest:
Stanford professor wins $500K MIT invention prize

American Oriental Bioengineering Announces Boke Subsidiary Passes Inspection

NEWARK, N.J., June 9, 2012 /PRNewswire-Asia-FirstCall/ --American Oriental Bioengineering, Inc., (the "Company" or "AOBI"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced that Boke Pharmaceutical Co, Ltd., one of the Company's wholly owned subsidiaries has passed the short notice inspections of its capsule products directed by China State Food and Drug Administration ("SFDA").

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

American Oriental Bioengineering, Inc.

Kewa Luo

(646) 367-1765

Read the original:
American Oriental Bioengineering Announces Boke Subsidiary Passes Inspection

A decade of innovation for health

For Immediate Release Monday, June 11, 2012

Media Advisory

More information: Registration and more information at http://www.nibib.nih.gov/NewsEvents/TenthAnniversary. This event will not be videocast.

About the National Institute of Biomedical Imaging and Bioengineering (NIBIB): NIBIBs mission is to support multidisciplinary research and research training at the crossroads of engineering and the biological and physical sciences. NIBIB supports emerging technology research and development within its internal laboratories and through grants, collaborations, and training. More information is available at the NIBIB website: http://www.nibib.nih.gov/.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH...Turning Discovery Into Health

Excerpt from:
A decade of innovation for health

Teachers experiment with fundraising pays off

Skip image

Brittany Hutchinson demonstrating the pipette that she raised money to fund. through the Donors Choose program.

By Whitney Hamrick | May 24, 2012

Teachers daunted by the shortage of school funding in Seminole County may have a source of relief.

Brittany Hutchinson, who teaches bioengineering at Lyman High School in Longwood, raised more than $700 to pay for micropipettes and other equipment through her partnership with a website called donorschoose.org.

"Ms. Hutchinson did a great job of promoting her project through donorschoose.org," said Tony Williams, who is the Horace Mann representative for Seminole County. "We work with the schools and we want to see the educators succeed."

Donors Choose is a nonprofit organization that provides a platform for donors and public school teachers to connect in order to fund necessary classroom materials they would otherwise have to do without in a tough economy.

The website was established by Horace Mann, an insurance company founded by teachers to focus on the financial needs of educators. The website was first launched in February 2011 and has since contributed $1.3 million to school projects nationwide.

Williams arrived in Seminole County three months ago, and during his search to learn more about the community, he found Hutchinson's profile.

The rest is here:
Teachers experiment with fundraising pays off

American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of …

NEWARK, N. J., May 31, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (AOBI) (the "Company"), today announced that it received written notification on May 25, 2012, from the NYSE Regulation, Inc. staff, on behalf of the New York Stock Exchange LLC ("NYSE"), that the staff had determined to immediately suspend trading in the common stock of the Company and file a delisting application with the United States Securities and Exchange Commission (the "SEC") pursuant to Section 804.00 of the Listed Company Manual. The staff stated in its notice that it had determined that the Company no longer meets the standard for continued listing on the NYSE and that it is necessary and appropriate for the protection of investors to immediately suspend trading in its common stock and initiate delisting proceedings.Trading in the Company's common stock on the NYSE had been halted since March 16, 2012.

As a result of the above actions, on Tuesday, May 29, 2012, the Company's common stock commenced quotation on the OTC Markets under the ticker symbol "AOBI."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release.The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

Kewa Luo 646-367-1765

Read more from the original source:
American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of ...

Wishbone Taps Power of the Net to Help At-Risk Kids

A non-profit startup called Wishbone is using the Internet to connect donors with underprivileged and at-risk kids hoping to participate in summer instructional programs in areas like computer science, bioengineering, art, and fashion.

Wishbone was founded in 2008 by former Teach for America high school English teacher Beth Schmidt but only recently launched Wishbone.org, a digital meeting ground for students needing assistance to attend summer programs and potential sponsors.

Profiles of students participating in the program indicate the areas of summer study they'd like to pursue, the idea being that would-be sponsors can more easily find a student whose interests match their own, according to Reed Matheny, outreach coordinator for Wishbone.org.

"We've had some good momentum since we've launched. We've been able to fully fund 12 of our students now," Matheny told PCMag recently. "They're ready to go to their summer programs. More than 50 percent of the rest are pretty close to being fully funded as well."

Wishbone is currently open to 9th through 12th graders from low-income families at a dozen schools located in New York and San Francisco, but hopes to expand to other schools and cities, Matheny said. The non-profit may also expand its mission to sponsor students for programs offered during the school year in addition to its summer program activities.

The initial online effort has already turned up some interesting data. Matheny said most sponsored students have received a steady stream of small donations rather than big lump sums, for example.

"So far it's been a big collection of smaller donations. A huge number of people are coming in and donating like $25 or even just $10. We do have some bigger donors who'll find a student they really like and donate $250 or something really sizable," he said.

For safety and propriety reasons, students and sponsors don't directly communicate. But Wishbone.org does post "success stories" about students who've secured funding for a summer program. Profiles include video messages from the students themselves and donors can also read about a sponsored student's experiences at an instructional program like the UC Davis Cosmos Camp, which one Wishbone student interested in bioengineering will attend this year.

Other Wishbone kids are headed for fashion design and technology camps in New York this summer, and a couple of Bay Area kids will attend an art program at San Francisco's Academy of Art, Matheny said.

Several students still need funding for their summer camp dreams, he noted. The good news is that those programs don't start until late June and July, so there's plenty of time for interested PCMag readers to head over to Wishbone.org and contribute to a deserving student's cause.

Go here to see the original:
Wishbone Taps Power of the Net to Help At-Risk Kids

Researchers in Singapore develop cancer stem cell biochip

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturised biochip, the Droplet Array, to investigate the effect of drugs on cancer stem cells. -- PHOTO: IBN

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) have developed a miniaturised biochip to investigate the effect of drugs on cancer stem cells.

The miniaturised biological assay, dubbed the Droplet Array and developed by a team of researchers led by IBN executive director, Professor Jackie Y. Ying, will make it easier for drug screenings using limited samples.

The new technology could boost the development of more effective cancer drugs, according to a statement released by IBN.

In a tumour, cancer stem cells form a small and distinct class of cancer cells that are more resistant to chemotherapy. They can produce and differentiate into different cell types. If they are not eradicated, they can cause cancer to recur.

More here:
Researchers in Singapore develop cancer stem cell biochip

Bioengineering May Relocate To Allston

Bioengineering, an academic unit of the School of Engineering and Applied Sciences, is on the table to move to Allston, according to several University officials.

According to University Provost Alan M. Garber 76, the Harvard administrators are considering moving portions of bioengineering, a growing sector within SEAS, to its proposed Allston Science Centerwhich was originally conceptualized as a mecca for stem cell researchupon the sites completion.

Garber said that University officials have yet to finalize academic planning for Allston.

Well have more to say about our academic direction for the building in June, but among the groups that seem to be particularly promising fits for Allston are bioengineering and stem-cell research, Garber said.

Kevin Casey, University associate vice president of public affairs and communications, said that Harvard is carefully considering its options for Allston development.

For each area, the provost has been meeting extensively with faculty and deans to further develop the plans in each area, and with fundraising leadership to determine possible strategies for philanthropic support, Casey wrote in an email. This planning process is ongoing.

SEAS Dean Cherry A. Murray, who also serves as the area dean for bioengineering, declined to comment.

In 2007, the University released its Institutional Master Plan for Allston, which included the creation of a $1 billion science complex in Allston. in Allston. However, development on the Allston Science Complex was halted in 2009 when the financial crisis delivered a significant blow to the University endowment.

In 2011, the University resumed planning for Allston development, including the its science complexnow called the Allston Science Center.

The development of the Allston Science Center is just one piece of the two-phase plan for Allston construction released by University Executive Vice President Katie N. Lapp.

Read the rest here:
Bioengineering May Relocate To Allston

NanoInk Expands Presence in Japan With Prestigious New Distributor

CHICAGO, IL--(Marketwire -05/15/12)- The NanoFabrication Systems Division of NanoInk is pleased to announce that it has reached a non-exclusive agreement with the Research Institute of Biomolecule Metrology Co., Ltd. (RIBM) to serve as a distributor in Japan. RIBM will distribute NanoInk's desktop nanofabrication equipment, including the NLP 2000 System and the DPN 5000 System, which has a wide range of applications ranging from nanoarray-based protein analysis to nano-bioengineering and biomaterial research. As a leader in the visualization and measurement of biomolecules, RIBM aims to spearhead technological advancements in the field of nano-biotechnology.

"RIBM is a leading player in the Japanese nano-biology industry and has already established a strong relationship with NanoInk's target customers in Japan. Its sales and technical teams have the in-depth knowledge required to understand the scientific instrument market and it has proven expertise in selling technically-sophisticated equipment into that space. With these strengths, RIBM is the ideal partner for driving sales of NanoInk's unique nanofabrication platforms for use in life science and bioengineering applications," said Oliver Yeh, General Manager, NanoInk's NanoFabrication Systems Division, Asia-Pacific region. "We look forward to a close and successful long-term partnership with RIBM as we expand our reach in Japan by promoting the unique capabilities and benefits of the NanoInk line of patterning systems."

"We are delighted to be appointed as a distributor for NanoInk's products in Japan's life science and bioengineering markets," said Dr. Takashi Morii, Director of the Biomolecule Metrology Division at RIBM. "NanoInk's product lines are complementary to our current product portfolio and are attractive to our targeted nano-biotechnology markets. We look forward to working with the NanoInk team."

NanoInk's NanoFabrication Systems Division brings sophisticated nanofabrication to the laboratory in an easy to use and affordable platform. NanoInk's NLP 2000 System is a desktop instrument that allows researchers to rapidly design and create custom engineered and functionalized surfaces by using Dip Pen Nanolithography (DPN) to transfer minute amounts of materials over a large, environmentally controlled work area. With the ability to create custom patterns of nano-to-microscale features in under an hour, the NLP 2000 System is valuable for protein and biomolecular patterning, microstructure and biosensor functionalization, cell biology and polymer printing applications.

The DPN 5000 System is a full-featured, dedicated instrument for versatile nanopatterning of a variety of materials with nanoscale accuracy and precision. With its user-friendly interface, it is possible to easily design complex patterns while also precisely controlling tip movements during the writing process. The DPN 5000 System is the ideal platform for nanofabrication, nanomaterials and biomaterials applications that exhibit nanoscale printing, imaging and registration requirements.

With locations in Tsukuba, Tokyo, and Hiroshima, RIBM specializes in biomolecule metrology, molecular imaging and food & environmental analysis applications. It develops, manufactures, and sells SPM equipment and conducts contract measurement services using SPM. In addition, it manufactures and sells high-speed AFM for biology which can capture movie images of moving molecules. RIBM also markets nano-measurement equipment and inspects food and environmental samples for genetic modifications, allergens, viruses and residual agricultural chemicals.

To obtain more information or to place an order through RIBM for NanoInk's desktop nanofabrication systems, please email Dr. Takashi Morii at morii@ribm.co.jp. More background on RIBM is available at: http://www.ribm.co.jp/index-e.htm.

For information on additional NanoInk distributors, visit: http://nanoink.net/distributors.html. More detail about the NanoFabrication Systems Division of NanoInk is available at: http://www.nanoink.net/divisions.html#NanoFabrication.

About NanoInkNanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography (DPN), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has several divisions including the NanoFabrication Systems Division, the Nano BioDiscovery Division, the NanoProfessor Division and the NanoGuardian Division. For more information on products and services offered by NanoInk, Inc., visit http://www.nanoink.net.

NanoInk, the NanoInk logo, Dip Pen Nanolithography, DPN, and NanoProfessor are registered trademarks of NanoInk, Inc.

Excerpt from:
NanoInk Expands Presence in Japan With Prestigious New Distributor

When cells hit the wall: UCLA engineers put the squeeze on cells to diagnose disease

Public release date: 30-Apr-2012 [ | E-mail | Share ]

Contact: Wileen Wong Kromhout wwkromhout@support.ucla.edu 310-206-0540 University of California - Los Angeles

If you throw a rubber balloon filled with water against a wall, it will spread out and deform on impact, while the same balloon filled with honey, which is more viscous, will deform much less. If the balloon's elastic rubber was stiffer, an even smaller change in shape would be observed.

By simply analyzing how much a balloon changes shape upon hitting a wall, you can uncover information about its physical properties.

Although cells are not simple sacks of fluid, they also contain viscous and elastic properties related to the membranes that surround them; their internal structural elements, such as organelles; and the packed DNA arrangement in their nuclei. Because variations in these properties can provide information about cells' state of activity and can be indicative of diseases such as cancer, they are important to measure.

UCLA bioengineering researchers have taken advantage of cells' physical properties to develop a new instrument that slams cells against a wall of fluid and quickly analyzes the physical response, allowing for the identification of cancer and other cell states without expensive chemical tags.

The instrument, called a deformability cytometer, was developed by UCLA biomedical engineering doctoral students Daniel Gossett and Henry Tse and assistant professor of bioengineering Dino Di Carlo. It consists of a miniaturized microfluidic chip that sequentially aligns cells so that they hit a wall of fluid at rates of thousands of cells per second. A specialized camera captures microscopic images of these cells at a rate of 140,000 pictures per second, and these images are then automatically analyzed by custom software to extract information about the cells' physical properties.

Other researchers had previously discovered that the physical properties of cells could provide useful information about cell health, but previous techniques had been confined to academic research labs because measuring the cells of interest could take hours or even days. With the deformability cytometer, the group can prepare samples and conduct an analysis of tens of thousands of cells within 10 to 30 minutes.

"Our system makes use of an approach that (U.S. Secretary of Energy) Steven Chu used to stretch DNA to, instead, stretch cells," Di Carlo said. "This required us to engineer the fluid dynamics of the system such that cells always entered the stretching flow in the same place, making use of inertial focusing technology my group has been pioneering."

With a system in place to measure the physical properties of cells at much higher rates, the bioengineers teamed up with collaborators across the UCLA campus to measure various cell populations of interest to biologists and doctors.

Read the rest here:
When cells hit the wall: UCLA engineers put the squeeze on cells to diagnose disease

:: 09, May 2012 :: IBN’S DROPLET ARRAY SHEDS LIGHT ON DRUG-RESISTANT CANCER STEM CELLS

MEDIA RELEASE

IBNs Droplet Array Sheds Light on Drug-Resistant Cancer Stem Cells

Singapore, May 9, 2012 Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the worlds first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.

In a tumor, CSCs form a small and distinct class of cancer cells that are more resistant to chemotherapy. Similar to stem cells found in human tissues, CSCs can produce and differentiate into different cell types. If CSCs are not eradicated, they can repopulate the tumor and lead to cancer recurrence. Hence, it is important for researchers to understand the efficacy of anti-cancer drugs against CSCs. However, since CSCs are so scarce they make up approximately 1% of cancer cells their study has been hampered by conventional drug screening methods, which require large sample volumes and are slow and expensive.

A team of researchers led by IBN Executive Director, Professor Jackie Y. Ying, has developed a miniaturized biological assay called the Droplet Array to perform cheaper, faster and more convenient drug screening using limited samples.

In traditional biological assays, microplates a flat plate with multiple wells in which samples are placed are commonly used, and each well requires at least 2,500 or 5,000 cells, to be present for viable analysis. By comparison, IBNs Droplet Array is a flat, rectangular glass plate on which a series of spots, each 2 millimeters in diameter, are arranged. The samples are pipetted into these tiny spots, making them appear like droplets. The plate is then coated with a layer of proprietary oil to prevent evaporation and cross contamination between the sample droplets during the rinsing process. An accompanying bench-top device to automate the rinsing process of the plate has also been developed. Being one-fifth the size of a well in a standard microplate, each spot on IBNs Droplet Array requires only 500 cells for screening. This massive reduction in sample volume not only saves money, but is also particularly advantageous for studying scarce quantities of target cells, such as CSCs.

Using the Droplet Array, the IBN researchers investigated the drug responses of CSCs extracted from breast, liver and colon cancer cells. It was found that chemotherapeutic drugs such as doxorubicin, which usually induce cell death in liver cancer cells, demonstrated poor efficacy in liver CSCs. The CSCs from the breast and colon tumors also showed much greater ability to survive the effects of anti-cancer drugs.

Animal studies were conducted to validate the findings of the Droplet Array. CSCs and non-CSCs from liver tumors were implanted into two different sets of mice at the same time. After 6 weeks, tumors were formed in the mice implanted with CSCs, whereas the mice without CSCs did not develop any tumors. Tumors extracted from the mice with CSCs also showed blood vessel formation, which confirmed the self-renewal property of these cells.

The drug resistance properties of CSCs have been widely discussed in recent years but until now, it has been challenging to quantify this correlation. Using the Droplet Array, IBN researchers have successfully demonstrated that CSCs can survive chemotherapy and drive metastasis.

Professor Jackie Y. Ying said, The Droplet Array marks a significant breakthrough in nanotechnology and lab-on-a-chip concepts, and provides an efficient platform for accelerating drug screening and development. The study of cancer stem cells, in particular, is an exciting application of this technology for both the academic and pharmaceutical industries. We hope that this finding will facilitate the development of more effective cancer drugs. We also hope to leverage on the Droplet Arrays capabilities to complement/replace animal models for drug toxicity testing, and develop new cancer diagnostics.

Read more from the original source:
:: 09, May 2012 :: IBN’S DROPLET ARRAY SHEDS LIGHT ON DRUG-RESISTANT CANCER STEM CELLS

'Blinking Microbubbles' for Early Cancer Screening Take Grand Prize at Research Expo 2012

This news release and any accompanying images can be accessed on the web at: http://ucsdnews.ucsd.edu/pressreleases/ blinking_microbubbles_for_early_cancer_screening _take_grand_prize_at_resear/ Blinking microbubbles for early cancer screening take grand prize at Research Expo 2012

Newswise Carolyn Schutt, a Ph.D student in bioengineering at the University of California, San Diego is developing a new imaging technique that could lead to highly-sensitive light imaging deeper inside the body, improving the way we diagnose breast cancer. Schutts research, which was entered in the nanoengineering category, received the grand prize April 12 at the UC San Diego Jacob School of Engineering Research Expo 2012.

Schutt's aim is to build a bridge between optical imaging and ultrasound imaging, in order to get the benefits of both technologies: the chemical sensitivity of visible light and the tissue penetrating properties of ultrasound. Such a "smart particle contrast agent" would render biological tissue effectively transparent to light and enable highly sensitive light imaging deeper inside the body, improving the way we diagnose cancer. Conventional X-ray mammography can only show the density of tissue, indicating the presence of a mass, but cannot determine any of the biochemical differences between a benign mass and a malignant tumor.

There is a very high false positive rate with just X-ray mammography, said Schutt, who was honored with the best poster award for the Department of NanoEngineering and Jacobs School-wide Rudee Outstanding Poster Award. By being able to extract chemical information we hope to avoid unnecessary biopsies that are done on benign lesions.

For example, because of their rapid growth, cancerous tumors consume a lot of oxygen so the area around a tumor is likely to be hypoxic or depleted of oxygen. Cancer cells also require increased blood flow to fuel their growth creating a region of new blood vessel formation. The use of this technique could allow this sort of biochemical information to be determined for tumor diagnosis.

Schutts work, advised by nanoengineering Professor Sadik Esener, focuses on the use of gas-filled microbubble contrast agents that change their fluorescence intensity, or blink, only in response to focused ultrasound. A solution of these microbubbles would be injected into the body to circulate through the blood stream. When gas microbubbles encounter an ultrasound pressure wave, they contract and expand their outer surface in response to the pressure peaks and troughs. By loading the microbubble surface with a fluorescent dye that turns off when it is very close to other dye molecules the ultrasound creates a blinking signal. Initially, less than 10 percent of the bubbles produced this modulating fluorescence. Analysis of the nanostructure by super-resolution microscopy showed that most of the dye partitioned into isolated clusters, which were likely preventing the dye from blinking in response to ultrasound. Schutt was able to manipulate the bubble nanostructure by heating the bubbles to melt their outer surface and distribute the dye more evenly, and then rapidly cooling them to lock in this distributed state. This melting and quick cooling process increased the fraction of blinking microbubbles to over 50 percent, making this a more viable imaging platform.

This blinking light can then be used to build up an image of the ultrasound-scanned tissue (a suspected tumor, for example) with the sensitivity and contrast offered by optical imaging. This is a new and powerful capability that could significantly improve present diagnostics as well as image guided therapeutic capabilities. In addition to NanoEngineering, Esener is affiliated with the departments of Electrical and Computer Engineering and Computer Science and Engineering, and UC San Diego Moores Cancer Center and director of the multi-institutional NanoTumor Center.

Schutt is also active in campus outreach and leadership programs. As a Gordon Scholar, Schutt participates in the Gordon Engineering Leadership Centers engineering leadership programs, a course of study Schutt takes seriously. In her current position as outreach chair of the Bioengineering Graduate Student Society, Schutt organized the groups exhibit at the recent San Diego Festival of Science and Engineering as well as a festival-wide science challenge for K-12 students to learn and discuss key science concepts. Read our chat with Schutt about organizing the Home Run Science Challenge.

Schutt was one of more than 230 graduate students who presented at Research Expo, which was sponsored by Qualcomm, ViaSat and SAIC. Judges were impressed by the students high level of technical proficiency and their ability to communicate their ideas.

Three-time Research Expo Judge Silvia De Dea, a staff scientist at Cymer, which is a member of the Jacobs School Corporate Affiliates Program, was impressed by the entrepreneurial mindset of many of the students she met who already had some experience with the patent process, including thinking about how their technology could be eventually sold or licensed to industry. Realizing that they had that type of mindset was very interesting, said De Dea, a Jacobs School alumna who earned a masters (2004) and doctorate (2008) in chemical engineering.

Read the original post:
'Blinking Microbubbles' for Early Cancer Screening Take Grand Prize at Research Expo 2012

Cancer screening technique wins research prize

SAN DIEGO Carolyn Schutt, a Ph.D student in bioengineering at the University of California, San Diego is developing a new imaging technique that could lead to highly-sensitive light imaging deeper inside the body, improving the way we diagnose breast cancer. Schutts research, which was entered in the nanoengineering category, received the grand prize April 12 at the UC San Diego Jacobs School of Engineering Research Expo 2012.

Schutt's aim is to build a bridge between optical imaging and ultrasound imaging, in order to get the benefits of both technologies: the chemical sensitivity of visible light and the tissue penetrating properties of ultrasound. Such a "smart particle contrast agent" would render biological tissue effectively transparent to light and enable highly sensitive light imaging deeper inside the body, improving the way we diagnose cancer. Conventional X-ray mammography can only show the density of tissue, indicating the presence of a mass, but cannot determine any of the biochemical differences between a benign mass and a malignant tumor.

There is a very high false positive rate with just X-ray mammography, said Schutt, who was honored with the best poster award for the Department of NanoEngineering and Jacobs School-wide Rudee Outstanding Poster Award. By being able to extract chemical information we hope to avoid unnecessary biopsies that are done on benign lesions.

For example, because of their rapid growth, cancerous tumors consume a lot of oxygen so the area around a tumor is likely to be hypoxic or depleted of oxygen. Cancer cells also require increased blood flow to fuel their growth creating a region of new blood vessel formation. The use of this technique could allow this sort of biochemical information to be determined for tumor diagnosis.

Schutts work, advised by nanoengineering professor Sadik Esener, focuses on the use of gas-filled microbubble contrast agents that change their fluorescence intensity, or blink, only in response to focused ultrasound. A solution of these microbubbles would be injected into the body to circulate through the blood stream. When gas microbubbles encounter an ultrasound pressure wave, they contract and expand their outer surface in response to the pressure peaks and troughs. By loading the microbubble surface with a fluorescent dye that turns off when it is very close to other dye molecules the ultrasound creates a blinking signal. Initially, less than 10 percent of the bubbles produced this modulating fluorescence. Analysis of the nanostructure by super-resolution microscopy showed that most of the dye partitioned into isolated clusters, which were likely preventing the dye from blinking in response to ultrasound. Schutt was able to manipulate the bubble nanostructure by heating the bubbles to melt their outer surface and distribute the dye more evenly, and then rapidly cooling them to lock in this distributed state. This melting and quick cooling process increased the fraction of blinking microbubbles to over 50 percent, making this a more viable imaging platform.

This blinking light can then be used to build up an image of the ultrasound-scanned tissue (a suspected tumor, for example) with the sensitivity and contrast offered by optical imaging. This is a new and powerful capability that could significantly improve present diagnostics as well as image guided therapeutic capabilities. In addition to NanoEngineering, Esener is affiliated with the departments of Electrical and Computer Engineering and Computer Science and Engineering, and UC San Diego Moores Cancer Center and director of the multi-institutional NanoTumor Center.

Schutt is also active in campus outreach and leadership programs. As a Gordon Scholar, Schutt participates in the Gordon Engineering Leadership Centers engineering leadership programs, a course of study Schutt takes seriously. In her current position as outreach chair of the Bioengineering Graduate Student Society, Schutt organized the groups exhibit at the recent San Diego Festival of Science and Engineering as well as a festival-wide science challenge for K-12 students to learn and discuss key science concepts. Read our chat with Schutt about organizing the Home Run Science Challenge.

Schutt was one of more than 230 graduate students who presented at Research Expo, which was sponsored by Qualcomm, ViaSat and SAIC. Judges were impressed by the students high level of technical proficiency and their ability to communicate their ideas.

Three-time Research Expo judge Silvia De Dea, a staff scientist at Cymer, which is a member of the Jacobs School Corporate Affiliates Program, was impressed by the entrepreneurial mindset of many of the students she met who already had some experience with the patent process, including thinking about how their technology could be eventually sold or licensed to industry. Realizing that they had that type of mindset was very interesting, said De Dea, a Jacobs School alumna who earned a masters (2004) and doctorate (2008) in chemical engineering.

Judge Greg Kusinski, DeepStar director with Chevron Energy Technology Co., who serves on the Industrial Advisory Board for the Department of NanoEngineering, said the winners demonstrated a unique capacity to explain the relevance of their research. The students had the ability to present the big picture, said Kusinski. Thats why they stood out. He said that they did a great job at showing the problem they were trying to solve, steps taken during the research process and the next steps in their research.

View post:
Cancer screening technique wins research prize

When cells hit the wall: Engineers put the squeeze on cells to diagnose disease

ScienceDaily (May 1, 2012) If you throw a rubber balloon filled with water against a wall, it will spread out and deform on impact, while the same balloon filled with honey, which is more viscous, will deform much less. If the balloon's elastic rubber was stiffer, an even smaller change in shape would be observed.

By simply analyzing how much a balloon changes shape upon hitting a wall, you can uncover information about its physical properties.

Although cells are not simple sacks of fluid, they also contain viscous and elastic properties related to the membranes that surround them; their internal structural elements, such as organelles; and the packed DNA arrangement in their nuclei. Because variations in these properties can provide information about cells' state of activity and can be indicative of diseases such as cancer, they are important to measure.

UCLA bioengineering researchers have taken advantage of cells' physical properties to develop a new instrument that slams cells against a wall of fluid and quickly analyzes the physical response, allowing for the identification of cancer and other cell states without expensive chemical tags.

The instrument, called a deformability cytometer, was developed by UCLA biomedical engineering doctoral students Daniel Gossett and Henry Tse and assistant professor of bioengineering Dino Di Carlo. It consists of a miniaturized microfluidic chip that sequentially aligns cells so that they hit a wall of fluid at rates of thousands of cells per second. A specialized camera captures microscopic images of these cells at a rate of 140,000 pictures per second, and these images are then automatically analyzed by custom software to extract information about the cells' physical properties.

Other researchers had previously discovered that the physical properties of cells could provide useful information about cell health, but previous techniques had been confined to academic research labs because measuring the cells of interest could take hours or even days. With the deformability cytometer, the group can prepare samples and conduct an analysis of tens of thousands of cells within 10 to 30 minutes.

"Our system makes use of an approach that (U.S. Secretary of Energy) Steven Chu used to stretch DNA to, instead, stretch cells," Di Carlo said. "This required us to engineer the fluid dynamics of the system such that cells always entered the stretching flow in the same place, making use of inertial focusing technology my group has been pioneering."

With a system in place to measure the physical properties of cells at much higher rates, the bioengineers teamed up with collaborators across the UCLA campus to measure various cell populations of interest to biologists and doctors.

Along with UCLA stem cell biologist Amander Clark, an assistant professor of of molecular, cellular and developmental biology, Di Carlo's team confirmed that stem cells that have the capability to become any tissue type stretch much less than their progeny, which are already in the process of becoming a particular tissue.

In collaboration with cytopathologist Dr. Jian Yu Rao, a professor of pathlogy and laboratory medicine at the David Geffen School of Medicine at UCLA, the team accurately detected cancer cells from pleural fluids using the high-speed deformability cytometer. Pleural fluid, which builds up around the lungs, is traditionally challenging to analyze because it contains a mixture of cell types -- including immune cells, mesothelial cells from the chest wall lining and, potentially, low concentrations of cancer cells.

Read the original post:
When cells hit the wall: Engineers put the squeeze on cells to diagnose disease

IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability – A Promising Discovery for Breast Cancer Therapy

Despite decades of cancer research, cancer remains a leading cause of death worldwide, accounting for 7.6 million deaths in 2008, and breast cancer is one of the most common causes of cancer deaths each year . In Singapore, more than 1,400 women are diagnosed with breast cancer and more than 300 die as a result of breast cancer each year . The high fatality rate of cancer is partially attributed to the invasive ability of malignant tumors to spread throughout the human body, and the ineffectiveness of conventional therapies to eradicate the cancer cells.

A team of researchers led by IBN Group Leader, Dr Shu Wang, has made a landmark discovery that neural stem cells (NSCs) derived from human induced pluripotent stem (iPS) cells could be used to treat breast cancer. The effectiveness of using NSCs, which originate from the central nervous system, to treat brain tumors has been investigated in previous studies. This is the first study that demonstrates that iPS cell-derived NSCs could also target tumors outside the central nervous system, to treat both primary and secondary tumors.

To test the efficiency of NSCs in targeting and treating breast cancer, the researchers injected NSCs loaded with a suicide gene (herpes simplex virus thymidine) into mice bearing breast tumors. They did this using baculoviral vectors or gene carriers engineered from an insect virus (baculovirus), which does not replicate in human cells, making the carriers less harmful for clinical use. A prodrug (ganciclovir), which would activate the suicide gene to kill the cancerous cells upon contact, was subsequently injected into the mice. A dual-colored whole body imaging technology was then used to track the distribution and migration of the iPS-NSCs.

The imaging results revealed that the iPS-NSCs homed in on the breast tumors in the mice, and also accumulated in various organs infiltrated by the cancer cells such as the lung, stomach and bone. The survival of the tumor-bearing mice was prolonged from 34 days to 39 days. This data supports and explains how engineered iPS-NSCs are able to effectively seek out and inhibit tumor growth and proliferation.

Dr Shu Wang shared, "We have demonstrated that tumor-targeting neural stem cells may be derived from human iPS cells, and that these cells may be used in combination with a therapeutic gene to cripple tumor growth. This is a significant finding for stem cell-based cancer therapy, and we will continue to improve and optimize our neural stem cell system by preventing any unwanted activation of the therapeutic gene in non-tumor regions and minimizing possible side effects."

"IBN's expertise in generating human stem cells from iPS cells and our novel use of insect virus carriers for gene delivery have paved the way for the development of innovative stem cell-based therapies. With their two-pronged attack on tumors using genetically engineered neural stem cells, our researchers have discovered a promising alternative to conventional cancer treatment," added Professor Jackie. Y. Ying, IBN Executive Director.

Compared to collecting and expanding primary cells from individual patients, IBN's approach of using iPS cells to derive NSCs is less laborious and suitable for large-scale manufacture of uniform batches of cellular products for repeated patient treatments. Importantly, this approach will help eliminate variability in the quality of the cellular products, thus facilitating reliable comparative analysis of clinical outcomes.

Additionally, these iPS cell-derived NSCs are derived from adult cells, which bypass the sensitive ethical issue surrounding the use of human embryos, and since iPS cells are developed from a patient's own cells, the likelihood of immune rejection would be reduced.

References: 1. J. Yang, D. H. Lam, S. S. Goh, E. X. L. Lee, Y. Zhao, F. Chang Tay, C. Chen, S. Du, G. Balasundaram, M. Shahbazi, C. K. Tham, W. H. Ng, H. C. Toh and S. Wang, "Tumor Tropism of Intravenously Injected Human Induced Pluripotent Stem Cell-derived Neural Stem Cells and their Gene Therapy Application in a Metastatic Breast Cancer Model," Stem Cells, (2012) DOI: 10.1002/stem.1051.

2. E. X. Lee, D. H. Lam, C. Wu, J. Yang, C. K. Tham and S. Wang, "Glioma Gene Therapy Using Induced Pluripotent Stem Cell-Derived Neural Stem Cells," Molecular Pharmaceutics, 8 (2011) 1515-1524.

Read the original post:
IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability - A Promising Discovery for Breast Cancer Therapy